ACCEL-QUETIAPINE 300 MG — DIN 02400383
QUETIAPINE (QUETIAPINE FUMARATE) : 300 MG · ACCEL PHARMA INC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ACCEL-QUETIAPINE?
ACCEL-QUETIAPINE 300 MG contains QUETIAPINE (QUETIAPINE FUMARATE) : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02400383, held by ACCEL PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 27-Jan-2017. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is ACCEL-QUETIAPINE used for?
Accel-Quetiapine (quetiapine fumarate) is indicated for the management of the manifestations of schizophrenia. Accel-Quetiapine is indicated as monotherapy for the acute management of manic episodes associated with bipolar disorder and acute management of depressive episodes associated with bipolar I and bipolar II disorder.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Quetiapine cost around the world?
Quetiapine is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 7 | 137 | USD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 58 | 122 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 15 | 110 | CZK███.██ |
| Greece | producer price (ex-factory) | 94 | 94 | EUR███.██ |
| Saudi Arabia | public | 75 | 87 | SAR███.██ |
| South Africa | single exit price | 75 | 86 | ZAR███.██ |
| Australia | ex-manufacturer | 22 | 69 | AUD███.██ |
| Hungary | producer price (ex-factory) | 29 | 34 | HUF███.██ |
| Luxembourg | reimbursement | 18 | 18 | EUR███.██ |
| United Kingdom | hospital | 10 | 10 | GBP███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
768 pack listings across 404 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Quetiapine pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Quetiapine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
33 holders have a Canadian DIN containing Quetiapine, across 236 DINs, of which 93 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ACCORD HEALTHCARE INC | 10 | 10 | ACH-QUETIAPINE, ACH-QUETIAPINE FUMARATE XR | Sourceable in Canada |
| TEVA CANADA LIMITED | 15 | 9 | ACT QUETIAPINE, TEVA-QUETIAPINE, TEVA-QUETIAPINE XR | Sourceable in Canada |
| PRO DOC LIMITEE | 10 | 9 | PRO-QUETIAPINE, QUETIAPINE XR | Sourceable in Canada |
| CHEPLAPHARM ARZNEIMITTEL GMBH | 9 | 9 | SEROQUEL, SEROQUEL XR | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 9 | 9 | QUETIAPINE, QUETIAPINE XR | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 14 | 5 | SANDOZ QUETIAPINE, SANDOZ QUETIAPINE XR, SANDOZ QUETIAPINE XRT | Sourceable in Canada |
| PHARMASCIENCE INC | 6 | 5 | PMS-QUETIAPINE | Sourceable in Canada |
| NB PHARMA INC. | 5 | 5 | NB-QUETIAPINE XR | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 14 | 4 | JAMP QUETIAPINE FUMARATE, JAMP-QUETIAPINE, QUETIAPINE XR | Sourceable in Canada |
| ANGITA PHARMA INC. | 13 | 4 | AG-QUETIAPINE, AG-QUETIAPINE FUMARATE, AG-QUETIAPINE XR | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 10 | 4 | MINT-QUETIAPINE, MINT-QUETIAPINE XR | Sourceable in Canada |
| SANIS HEALTH INC | 9 | 4 | QUETIAPINE, QUETIAPINE FUMARATE XR | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 300 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Quetiapine |
|---|---|
| ATC code | N05AH04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02400383 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2400383 |
| Brand name | ACCEL-QUETIAPINE |
| Generic / active ingredient | QUETIAPINE (QUETIAPINE FUMARATE) : 300 MG |
| Market authorization holder | ACCEL PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | N05AH04 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05AH |
| Current status | CANCELLED POST MARKET |
| Status date | 27-Jan-2017 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Schizophrenia/Bipolar: Titrate daily. Hepatic impairment: Start at 25 mg/day, increase by 25-50 mg/day. Gradual withdrawal over 1-2 weeks recommended.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Known hypersensitivity to quetiapine fumarate or any of its ingredients.
Warnings and precautions
Serious Warning: Increased mortality in elderly patients with dementia. Risk of Neuroleptic Malignant Syndrome, Tardive Dyskinesia, QT prolongation, and metabolic changes.
Is Quetiapine in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by JAMP PHARMA CORPORATION, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
93 of 236 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-QUETIAPINE | 200 MG | TABLET (IMMEDIATE RELEASE) | ACCORD HEALTHCARE INC | MARKETED | 02387824 |
| ACH-QUETIAPINE | 300 MG | TABLET (IMMEDIATE RELEASE) | ACCORD HEALTHCARE INC | MARKETED | 02387832 |
| ACH-QUETIAPINE | 25 MG | TABLET (IMMEDIATE RELEASE) | ACCORD HEALTHCARE INC | MARKETED | 02387794 |
| ACH-QUETIAPINE | 100 MG | TABLET (IMMEDIATE RELEASE) | ACCORD HEALTHCARE INC | MARKETED | 02387808 |
| ACH-QUETIAPINE | 150 MG | TABLET (IMMEDIATE RELEASE) | ACCORD HEALTHCARE INC | MARKETED | 02387816 |
| ACH-QUETIAPINE FUMARATE XR | 200 MG | TABLET (EXTENDED-RELEASE) | ACCORD HEALTHCARE INC | MARKETED | 02450887 |
| ACH-QUETIAPINE FUMARATE XR | 50 MG | TABLET (EXTENDED-RELEASE) | ACCORD HEALTHCARE INC | MARKETED | 02450860 |
| ACH-QUETIAPINE FUMARATE XR | 150 MG | TABLET (EXTENDED-RELEASE) | ACCORD HEALTHCARE INC | MARKETED | 02450879 |
| ACH-QUETIAPINE FUMARATE XR | 300 MG | TABLET (EXTENDED-RELEASE) | ACCORD HEALTHCARE INC | MARKETED | 02450895 |
| ACH-QUETIAPINE FUMARATE XR | 400 MG | TABLET (EXTENDED-RELEASE) | ACCORD HEALTHCARE INC | MARKETED | 02450909 |
2 · Same class — other molecules in ATC N05AH
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Olanzapine | ABBOTT-OLANZAPINE ODT · ACCEL-OLANZAPINE · ACT OLANZAPINE · ACT OLANZAPINE ODT · +46 more | 271 | 103 | Yes |
| Quetiapine | ABBOTT-QUETIAPINE · ACCEL-QUETIAPINE · ACH-QUETIAPINE · ACH-QUETIAPINE FUMARATE XR · +43 more | 236 | 93 | Yes |
| Clozapine | AA-CLOZAPINE · AURO-CLOZAPINE · CLOZAPINE TABLETS · CLOZARIL · +3 more | 28 | 17 | Yes |
| Loxapine | APO-LOXAPINE · DOM-LOXAPINE TABLETS 10MG · DOM-LOXAPINE TABLETS 25MG · DOM-LOXAPINE TABLETS 50MG · +27 more | 51 | 4 | Yes |
| Asenapine | MINT-OLANZAPINE ODT · SAPHRIS | 3 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N05AX | Aripiprazole · Brexpiprazole · Cariprazine · Paliperidone · Risperidone | 352 | 175 |
| N05AE | Lurasidone · Ziprasidone | 60 | 41 |
| N05AB | Fluphenazine · Perphenazine · Prochlorperazine · Thioproperazine · Trifluoperazine | 104 | 10 |
| N05AD | Droperidol · Haloperidol | 53 | 9 |
| N05AF | Flupentixol · Tiotixene · Zuclopenthixol | 25 | 8 |
| N05AA | Chlorpromazine · Levomepromazine · Promazine | 51 | 8 |
| N05AN | Lithium | 26 | 7 |
| N05AC | Mesoridazine · Periciazine · Pipotiazine · Thioridazine | 32 | 3 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ACCEL-QUETIAPINE called?
The same molecule, Quetiapine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| QUETIAPINE VIATRIS | Latin | Czechia |
| QUETIAPIN NEURAXPHARM | Latin | Czechia |
| KETILEPT | Latin | Czechia |
| QUETIAPIN MYLAN | Latin | Czechia |
| DERIN PROLONG | Latin | Czechia |
| DERIN | Latin | Czechia |
| KVENTIAX | Latin | Czechia |
| KVENTIAX PROLONG | Latin | Czechia |
| Phreno XR | Latin | Saudi Arabia |
| QUETIAPIN TEVA RETARD | Latin | Czechia |
| APX-Quetiapine XR | Latin | Australia |
| Quetia XR | Latin | Australia |
| QUETIAPINE ACCORD | Latin | Czechia |
| Quetiapine Sandoz XR | Latin | Australia |
| Seroquel | Latin | Australia, South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.